US Government cuts to mRNA vaccine research could set technological advances, reduce access to therapies, and raise their ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

In an HHS video released yesterday on Fox News, Kennedy said that after consulting with experts from the National Institutes ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout.

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of manufacturing and R&D projects planned over the next five years.

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some credit due to its tariff policy and Presiden… ...

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new facility in Virginia.

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several manufacturing facilities in several states.

AstraZeneca Joins Pharma Investment Push in U.S. Amid Tariff Threat The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.